BIOXCEL THERAPEUT DL-,001 Forum: Community User: Adler.

Na dann tiefer geht ja nicht mehr, wäre zufrieden wenn es über ein dolar bleibt

Wäre im Februar das offerings nicht wäre der Kurs viel weiter. Keiner hat vertrauen mehr.

0,67 € aktuell ach du kacke was ist denn hier los 😂

Guten morgen, stehen alle unter schock, nur Ali bin laden nicht

Klavier Gangster

Egal wo ich recherchiere nur schlechte Analysen und co. Z score zu hoch. Seit Jahren geht der Preis nach unten.

Wenn sie Pleite wären, dann würde es steiler nach unten gehen und auch der von Ali thematisierte RS nicht kommen.

Ich will nicht beunruhigen aber bin laden hat glaube ich recht. Das Unternehmen ist so gut wie pleite

https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-second-quarter-2024-financial Ich finde, nur gute Sachen im Quartalsbericht.. Second Quarter 2024 Financial Results Net Revenue: Net revenue from IGALMI was $1.1 million for the second quarter of 2024, compared to $457 thousand for the same period in 2023, representing a 141% increase. Sequential quarterly revenue increased 90% in Q2 2024 from Q1 2024. The increased revenue for both periods was primarily driven by an increase in contracting with psychiatric care clinics and behavioral health facilities. Research and Development (R&D) Expenses: R&D expenses were $8.0 million for the second quarter of 2024, compared to $27.0 million for the same period in 2023. The decreased expenses were primarily attributable to the wind-down of the SERENITY III and TRANQUILITY II and III trials, as well as decreased professional fees, personnel, and related costs. Selling, General and Administrative (SG&A) Expenses: SG&A expenses were $9.5 million for the second quarter of 2024, compared to $25.9 million for the same period in 2023. The reduced expenses were primarily attributable to a decrease in personnel and costs associated with the commercialization of IGALMI compared to the second quarter of 2023, driven by the Company’s strategic reprioritization announced in August 2023. Net Loss: BioXcel Therapeutics had a net loss of $8.3 million for the second quarter of 2024**, compared to a net loss of $53.5 million for the same period in 2023. The Company used $23.2 million in operating cash during the second quarter of 2024.

Btai Ende nächster Woche?